Dr. Siegel on the PX-171-003-A1 Carfilzomib Study

David S. Siegel, MD, PhD
Published: Monday, Mar 14, 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains a phase IIb study that enrolled 266 heavily pretreated patients with multiple myeloma who were refractory/ intolerant to bortezomib and at least one immunomodulator, or disease-refractory to all five approved classes of treatment. Of these, 257 were evaluable for response and 266 for safety. Patients could receive up to 12 cycles of carfilzomib.

For the entire population, duration of response was a median of 7.8 months. Additionally, less peripheral neuropathy was observed in the patients receiving carfilzomib.

The FDA approved carfilzomib (Kyprolis) for patients with multiple myeloma who received at least two prior lines of therapy, on July 20, 2012.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains a phase IIb study that enrolled 266 heavily pretreated patients with multiple myeloma who were refractory/ intolerant to bortezomib and at least one immunomodulator, or disease-refractory to all five approved classes of treatment. Of these, 257 were evaluable for response and 266 for safety. Patients could receive up to 12 cycles of carfilzomib.

For the entire population, duration of response was a median of 7.8 months. Additionally, less peripheral neuropathy was observed in the patients receiving carfilzomib.

The FDA approved carfilzomib (Kyprolis) for patients with multiple myeloma who received at least two prior lines of therapy, on July 20, 2012.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in CareSep 29, 20181.5
1st Annual LIVE Medical Crossfire®: Expert Exchanges in Hematologic Malignancies OnlineSep 30, 20188.0
Publication Bottom Border
Border Publication
x